Mishina T, Kobayashi T, Maegawa M, Nakao M, Nakagawa S
Cancer Chemother Pharmacol. 1983;11 Suppl:S89-90. doi: 10.1007/BF00256727.
Our AFC regimen was originally developed to treat superficial bladder tumors. It consists of a daily intravesical administration of 20 mg Adriamycin (ADM) and 200 mg Cytosine arabinoside (CA) dissolved in 20 ml of sterilized distilled water, simultaneously with a daily rectal suppository of 750 mg tegafur (Futraful) for a total of 20 applications. Our study demonstrated the following characteristics of the AFC modality: (1) It is simple; (2) it is completed in 3 weeks, which is shorter than conventional bladder instillation therapy; (3) the effective rate is reasonable (70%); (4) no local side-effects were observed because the concentrations of ADM and CA were low; (5) interruption of therapy was unnecessary, because whatever general side-effects were caused, they disappeared within several days of completion of treatment.
我们的AFC方案最初是为治疗浅表性膀胱肿瘤而研发的。该方案包括每日膀胱内灌注溶解于20毫升灭菌蒸馏水中的20毫克阿霉素（ADM）和200毫克阿糖胞苷（CA），同时每日直肠栓剂使用750毫克替加氟（喃氟啶），共进行20次治疗。我们的研究展示了AFC治疗方式的以下特点：（1）操作简单；（2）3周内即可完成，比传统膀胱灌注疗法所需时间短；（3）有效率合理（70%）；（4）由于阿霉素和阿糖胞苷的浓度较低，未观察到局部副作用；（5）无需中断治疗，因为无论引起何种全身副作用，它们都会在治疗结束后的几天内消失。
